Overview

Treatment for Symptomatic Peripheral Neuropathy in Patients With Diabetes

Status:
Completed
Trial end date:
2005-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this protocol is to determine if an investigational drug is effective in treating nerve malfunction in diabetes.
Phase:
Phase 3
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Ruboxistaurin